Regulatory Roundup: FDA Issues Warning Letter To Pfizer; And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Issues Warning Letter To Pfizer; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Earlier this month, the US Food and Drug Administration issued a Warning Letter to the Global Research and Development division of Pfizer (New York) in London, Connecticut. The letter concerns an investigation that took place in spring 2009 which found that the manufacturer “did not adhere to the applicable statutory requirements and FDA regulations governing the conduct of clinical investigations.” Specifically, FDA pointed out the company’s failure to ensure proper monitoring of the investigation, including compliance with 21 CFR 312.50, and failure to keep investigators informed of new observations reported to the sponsor of the drug regarding adverse effects and safe use. Other recent Warning Letters can be found on the FDA CDER website.

FDA issued a consent decree last week to halt the marketing of an unapproved sterilization system manufactured by Steris (Mentor, OH). The company has been selling tabletop systems for endoscopes and other devices used to sterilize heat-sensitive instruments and medical devices. “When device manufacturers fail to comply with FDA’s regulations, they put patients at increased risk. As this consent decree shows, we will take whatever steps are necessary to make sure that all manufacturers are complying with FDA’s regulations,” said the FDA press release on the consent decree.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
38%
Breakthrough designations
13%
Protecting the supply chain
38%
Expedited reviews of drug submissions
13%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here